BOLD — Boundless Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $26.19m
- -$100.96m
Annual cashflow statement for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -25.2 | -45.9 | -49.4 | -65.4 |
| Depreciation | ||||
| Non-Cash Items | 2.12 | 4.5 | 2.42 | 5.11 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | -0.837 | 0.866 | -0.799 | -1.68 |
| Change in Prepaid Expenses | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | -23.2 | -39.6 | -46.9 | -60.8 |
| Capital Expenditures | -2.03 | -1.07 | -0.633 | -2.54 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -57.3 | 17.2 | -37.6 | -23.6 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -59.3 | 16.1 | -38.3 | -26.1 |
| Financing Cash Flow Items | — | 0 | -1.96 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 106 | 0.126 | 97.9 | 89.8 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 23 | -23.3 | 12.8 | 2.88 |